Cellosaurus logo
expasy logo

Cellosaurus HSJD-DIPG-007 (CVCL_VU70)

[Text version]
Cell line name HSJD-DIPG-007
Synonyms HSJD-DIPG007; DIPG007; Hospital Sant Joan de Deu-Diffuse Intrinsic Pontine Glioma-007
Accession CVCL_VU70
Resource Identification Initiative To cite this cell line use: HSJD-DIPG-007 (RRID:CVCL_VU70)
Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Omics: Deep exome analysis.
Derived from site: In situ; Brainstem, pons; UBERON=UBERON_0000988.
Sequence variations
  • Mutation; HGNC; 171; ACVR1; Simple; p.Arg206His (c.617G>A); ClinVar=VCV000018309; Zygosity=Unspecified (PubMed=27325687).
  • Mutation; HGNC; 4764; H3-3A; Simple; p.Lys28Met (c.83A>T) (H3.3K27M); ClinVar=VCV000376435; Zygosity=Unspecified (PubMed=27325687; PubMed=34732238).
  • Mutation; HGNC; 9277; PPM1D; Simple; p.Pro428Glnfs*3 (c.1283delC); Zygosity=Unspecified (PubMed=32229503; PubMed=34732238).
Disease Diffuse intrinsic pontine glioma (NCIt: C94764)
Diffuse intrinsic pontine glioma (ORDO: Orphanet_497188)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_C1MT (HSJD-DIPG-007-NTC)CVCL_C1MU (HSJD-DIPG-007-TP53 KO)
Sex of cell Male
Age at sampling 6Y
Category Cancer cell line
STR profile Source(s): PubMed=34732238

Markers:
AmelogeninX,Y
CSF1PO10
D5S81813
D7S8209,12
D13S31713
D16S53913,14
D21S1129,30
TH016,9.3
TPOX8
vWA16,17

Run an STR similarity search on this cell line
Publications

PubMed=25628092; DOI=10.1038/bjc.2015.16
Cockle J.V., Picton S., Levesley J., Ilett E., Carcaboso A.M., Short S., Steel L.P., Melcher A., Lawler S.E., Bruning-Richardson A.
Cell migration in paediatric glioma; characterisation and potential therapeutic targeting.
Br. J. Cancer 112:693-703(2015)

PubMed=27325687; DOI=10.1158/1535-7163.MCT-15-0558
Jansen M.H.A., Lagerweij T., Sewing A.C.P., Vugts D.J., van Vuurden D.G., Molthoff C.F.M., Caretti V., Veringa S.J.E., Petersen N., Carcaboso A.M., Noske D.P., Vandertop W.P., Wesseling P., van Dongen G.A.M.S., Kaspers G.J.L., Hulleman E.
Bevacizumab targeting diffuse intrinsic pontine glioma: results of 89Zr-bevacizumab PET imaging in brain tumor models.
Mol. Cancer Ther. 15:2166-2174(2016)

PubMed=28947132; DOI=10.1016/j.yexcr.2017.09.032
Meel M.H., Sewing A.C.P., Waranecki P., Metselaar D.S., Wedekind L.E., Koster J., van Vuurden D.G., Kaspers G.J.L., Hulleman E.
Culture methods of diffuse intrinsic pontine glioma cells determine response to targeted therapies.
Exp. Cell Res. 360:397-403(2017)

PubMed=31439867; DOI=10.1038/s41467-019-11732-6
Fons N.R., Sundaram R.K., Breuer G.A., Peng S., McLean R.L., Kalathil A.N., Schmidt M.S., Carvalho D.M., Mackay A., Jones C., Carcaboso A.M., Nazarian J., Berens M.E., Brenner C., Bindra R.S.
PPM1D mutations silence NAPRT gene expression and confer NAMPT inhibitor sensitivity in glioma.
Nat. Commun. 10:3790.1-3790.10(2019)

PubMed=32229503; DOI=10.1158/1541-7786.MCR-19-0507
Wang Z.-H., Xu C., Diplas B.H., Moure C.J., Chen C.-P.J., Chen L.H., Du C.-Z., Zhu H.-S., Greer P.K., Zhang L.-W., He Y.-P., Waitkus M.S., Yan H.
Targeting mutant PPM1D sensitizes diffuse intrinsic pontine glioma cells to the PARP inhibitor olaparib.
Mol. Cancer Res. 18:968-980(2020)

PubMed=34732238; DOI=10.1186/s40478-021-01270-y
Xu C., Liu H., Pirozzi C.J., Chen L.H., Greer P.K., Diplas B.H., Zhang L.-W., Waitkus M.S., He Y.-P., Yan H.
TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist.
Acta Neuropathol. Commun. 9:178.1-178.12(2021)

Cross-references
Cell line databases/resources cancercelllines; CVCL_VU70
Cell_Model_Passport; SIDM01714
DepMap; ACH-002348
Encyclopedic resources Wikidata; Q94303494
Entry history
Entry creation24-May-2019
Last entry update05-Oct-2023
Version number11